Latest & greatest articles for estradiol

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on estradiol or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on estradiol and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for estradiol

41. Lowest Effective Transdermal 17{beta}-Estradiol Dose for Relief of Hot Flushes in Postmenopausal Women: A Randomized Controlled Trial. (PubMed)

Lowest Effective Transdermal 17{beta}-Estradiol Dose for Relief of Hot Flushes in Postmenopausal Women: A Randomized Controlled Trial. OBJECTIVE: To investigate the efficacy of micro-dose transdermal estrogen in relieving menopausal vasomotor symptoms. METHODS: A randomized, double-blind, placebo-controlled, multi-center trial. Healthy postmenopausal women with at least seven moderate or severe hot flushes per day for at least 1 week, or at least 50 per week, applied transdermal patches (...) with a nominal delivery of 0.023 mg/d 17beta-estradiol and 0.0075 mg/d levonorgestrel (low-dose E2/levonorgestrel; n=145), 0.014 mg/d E2 (micro-dose; n=147), or placebo (n=133) for 12 weeks. The coprimary efficacy variables were the mean changes from baseline in frequency and severity of moderate and severe hot flushes at the week 4 and 12 endpoints. RESULTS: At the week 12 endpoint, mean weekly frequencies of moderate and severe hot flushes were significantly reduced compared with placebo with low-dose E2

Full Text available with Trip Pro

2007 EvidenceUpdates

42. Yaz (drospirenone 3mg/ethinyl estradiol 0.02mg)

Yaz (drospirenone 3mg/ethinyl estradiol 0.02mg) Drug Approval Package: YAZ (drospirenone 3mg/ethinyl estradiol 0.02mg) NDA #022045 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - YAZ (drospirenone 3mg/ethinyl estradiol 0.02mg) Tablets Company: Berlex, Inc. Application No.: 022045 Approval Date: 01/26/2007 (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date created: February 22, 2008 Updated: October 3, 2011 Note: Documents in PDF format require

2007 FDA - Drug Approval Package

43. Etonogestrel/ethinyl estradiol

Etonogestrel/ethinyl estradiol Common Drug Review CEDAC Meeting – October 18, 2006 Page 1 of 2 Notice of CEDAC Final Recommendation – November 29, 2006 CEDAC FINAL RECOMMENDATION and REASONS for RECOMMENDATION ETONOGESTREL/ETHINYL ESTRADIOL (NuvaRing TM - Organon Canada Ltd.) Description: NuvaRing TM is a contraceptive vaginal ring containing two active components, etonogestrel and ethinyl estradiol. Dosage Forms: NuvaRing TM contains 11.4 mg etonogestrel and 2.6 mg ethinyl estradiol (...) and releases, on average, 120 µg/day of etonogestrel and 15 µg/day of ethinyl estradiol over a three week period of use. Recommendation: The Canadian Expert Drug Advisory Committee (CEDAC) recommends that NuvaRing TM be listed on the condition that the amount paid by drug plans for NuvaRing TM per cycle not exceed the current maximum paid for oral contraceptives. Reasons for the Recommendation: 1. The Committee considered a systematic review of randomized controlled trials (RCTs) of at least six months

2007 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

44. Yaz (drospirenone/ethinyl estradiol) for Oral Contraception and Premenstrual Dysphoric Disorder

Yaz (drospirenone/ethinyl estradiol) for Oral Contraception and Premenstrual Dysphoric Disorder Drug Approval Package: Yaz (drospirenone/ethinyl estradiol) NDA #021873 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Yaz (drospirenone/ethinyl estradiol) for Oral Contraception and Premenstrual Dysphoric Disorder Company: Berlex, Inc. NDA: 021873 Approval Date: 10/4/2006 (PDF) (PDF) (PDF) Medical Review(s) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

2006 FDA - Drug Approval Package

45. drospirenone /ethinyl estradiol

drospirenone /ethinyl estradiol CEDAC FINAL RECOMMENDATION and REASONS for RECOMMENDATION DROSPIRENONE / ETHINYL ESTRADIOL (Yasmin ® – Berlex Canada Inc.) Description: Yasmin® is a monophasic combination of drospirenone 3 mg and ethinyl estradiol 0.03 mg, approved for oral conception control. Recommendation: The Canadian Expert Drug Advisory Committee (CEDAC) recommends that the combination of drospirenone 3 mg and ethinyl estradiol 0.03 mg be listed. Reasons for the recommendation: 1. Efficacy (...) is similar to currently available monophasic combination oral contraceptives with different progestogen but same ethinyl estradiol concentration. 2. Safety appears to be similar to currently available monophasic combination oral contraceptives with different progestogen but same ethinyl estradiol concentration. 3. Cost is similar compared to currently available monophasic combination oral contraceptives with different progestogen but same ethinyl estradiol concentration. Of Note: 1. Drosperinone is a new

2005 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

46. norgelestromin/ethinyl estradiol

norgelestromin/ethinyl estradiol RECOMMENDATION on RECONSIDERATION and REASONS for RECOMMENDATION NORELGESTROMIN/ETHINYL ESTRADIOL transdermal patch (Evra—Janssen-Ortho Inc.) Description: Norelgestromin/ethinyl estradiol is a transdermal combination estrogen/progestin patch indicated for contraception. Recommendation on Reconsideration: CEDAC recommends that the norelgestromin/ethinyl estradiol transdermal patch not be listed. Reasons for the recommendation: 1. In the two randomized controlled (...) trials comparing the norelgestromin/ethinyl estradiol transdermal patch with oral contraceptives that evaluated pregnancy rates, the pregnancy rates were similar (pregnancy rate 0.6% vs 1.2%; 0.5% vs 0.3%). 2. In all 3 randomized trials that reported withdrawals, the withdrawal rate was higher in the patients receiving the transdermal patch. These differences were statistically significant in two trials. 3. In all 3 randomized controlled trials that reported withdrawals because of adverse effects

2004 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

47. Ultralow-dose micronized 17beta-estradiol and bone density and bone metabolism in older women: a randomized controlled trial. (PubMed)

Ultralow-dose micronized 17beta-estradiol and bone density and bone metabolism in older women: a randomized controlled trial. Estrogen therapy is known to prevent osteoporosis, but studies have shown that conventional doses increase adverse events. Whether lower doses, one quarter of standard treatment, prevent bone loss is not known.To examine the effect of 3 years of treatment with 0.25 mg/d of micronized 17beta-estradiol on bone mineral density (BMD) and bone turnover in healthy older (...) postmenopausal women.Randomized, double-blind, placebo-controlled trial conducted from July 24, 1998, through June 14, 2002, at a university general clinical research center in the United States. Healthy, community-dwelling women (N = 167) who were older than 65 years at enrollment.Dosage of 0.25 mg/d of micronized 17beta-estradiol (n = 83) or placebo (n = 84); all women who had not had a hysterectomy received 100 mg/d of oral micronized progesterone for 2-week periods every 6 months.The BMD of the hip

Full Text available with Trip Pro

2003 JAMA

48. Serum estradiol level and risk of breast cancer during treatment with raloxifene. (PubMed)

Serum estradiol level and risk of breast cancer during treatment with raloxifene. As endogenous estradiol increases, risk of breast cancer increases. Raloxifene competes with endogenous estrogen for binding to estrogen receptors in breast tissue. A woman's estradiol level may alter the effects of raloxifene on breast cancer and other outcomes.To test the hypothesis that raloxifene reduces breast cancer risk more in women with relatively high estradiol levels than in women with very low (...) estradiol levels.Analysis of the Multiple Outcomes of Raloxifene Evaluation, a randomized, double-blind, placebo-controlled trial conducted from 1994 to 1999.One hundred eighty community settings and medical practices in 25 countries including the United States.A total of 7290 postmenopausal women aged 80 years or younger with osteoporosis who had baseline serum estradiol concentrations measured by a central laboratory using a sensitive assay. Women with a history of breast cancer or estrogen use were

2002 JAMA

49. Plasma lipids and desogestrel and ethinyl estradiol: a meta-analysis

Plasma lipids and desogestrel and ethinyl estradiol: a meta-analysis Plasma lipids and desogestrel and ethinyl estradiol: a meta-analysis Plasma lipids and desogestrel and ethinyl estradiol: a meta-analysis Lobo R A, Skinner J B, Lippman J S, Cirillo S J Authors' objectives To review the literature to determine the magnitude of effect of 150 microg desogestrel combined with 30 microg ethinyl E2, an oral contraceptive (OC) formulation, on plasma lipid concentrations in healthy women using meta (...) , the review does provide good detail on the methods used to combine the primary studies and a thorough discussion. Bibliographic details Lobo R A, Skinner J B, Lippman J S, Cirillo S J. Plasma lipids and desogestrel and ethinyl estradiol: a meta-analysis. Fertility and Sterility 1996; 65(6): 1100-1109 PubMedID Indexing Status Subject indexing assigned by NLM MeSH Cholesterol /blood; Cholesterol, HDL /blood; Cholesterol, LDL /blood; Contraceptives, Oral /adverse effects /pharmacology; Desogestrel /adverse

1996 DARE.